Together, SpiroChem and EuroAPI want to offer a consolidated CRO-CDMO solution that integrates the industrialization requirements for small molecules from the first step of drug design.

“By adding a renowned CRO partner like SpiroChem to our existing R&D and industrial offering, this fruitful collaboration will strengthen our market position and accelerate our CDMO roadmap,” said Cécile Maupas, EuroAPI’s chief CDMO officer. “Together with EuroAPI’s production technologies, SpiroChem’s recognized capabilities in route scouting will enable us to provide customers with integrated customized solutions to make their chemical drug development shorter, greener and more cost-efficient.”

Thomas Fessard, CEO and co-founder of SpiroChem, commented: “Having EuroAPI as a partner brings a substantial value to SpiroChem’s customers who are looking for reliable CDMOs to rapidly and seamlessly scale up the innovative solutions developed by SpiroChem.” He added: “Time is of the essence in early CMC² and we are confident that this collaboration will greatly benefit our customer base, in particular by accelerating the transition from discovery to development for early-stage projects and the biotech segment.”